dostarlimab-gxly (JEMPERLI)

Indications

• treatment of adult patients with mismatch repair deficient recurrent or advanced endometrial cancer* that has progressed after cisplatin-based therapy

* determined by FDA-approved test

Contraindications

• pregnancy

Dosage

• 500 mg every 3 weeks (4 doses)
• thereafter 1000 mg every 6 weeks
• administer as IV infusion over 30 minutes

* Injection: 500 mg/10 mL in single dose vial

Adverse effects

• most common > 20%
  • fatigue/asthenia, nausea, diarrhea, anemia, constipation
• immune-mediated reactions
  • immune-mediated pneumonitis
  • immune-mediated colitis
  • immune-mediated hepatitis
  • immune-mediated endocrinopathies
  • immune-mediated nephritis
  • immune-mediated dermatologic adverse reactions
• infusion-related reactions
• complications of allogeneic hematopoietic stem cell transplantation
• embryo-fetal toxicity

• drug adverse effects of pharmaceutical monoclonal antibodies

Mechanism of action

• programmed death receptor-1 (PD-1)-blocking monoclonal antibody

More general terms

• antineoplastic monoclonal antibody